Skip to main content
. 2015 Jan 8;6(2):1031–1048. doi: 10.18632/oncotarget.2671

Figure 2. IL-6 stimulates NOX4/Akt pathway in A549 cells.

Figure 2

(A) ELISA analysis of IL-6 production in normal lung epithelial cells and cultured NSCLC cell lines. Bars are mean ± SD from four independent experiments. *Significantly different from BEAS2B cell group, P < 0.05. (B-D) The effects of IL-6 administration on NOX4 expression, ROS production and Akt activity in A549 cells at the indicated times, respectively. Bars are mean ± SD from four independent experiments. *Significantly different from control, P < 0.05. (E) The effect of IL-6 on STAT3 activity, and the influence of IL-6 neutralizing antibody siltuximab, JAKs inhibitor P6 (2.5 μM) or a selective JAK2 inhibitor of AG490 on IL-6-mediated STAT3 activation in A549 cells. (F-H) P6 or siltuximab could efficiently block the enhancement effects of IL-6 on NOX4 expression, ROS production and Akt activity in A549 cells after 48-hour incubation. Bars are mean ± SD from four independent experiments. *Significantly different from control, P < 0.05.